ScinoPharm www'scinopharm'com

1
ScinoPharmwww.scinopharm.com

• UBS Global Pharma Conference
• Grand Hyatt Hotel
• New York
• May 23, 2005

2
Disclaimer

• This material has been prepared by ScinoPharm
  Taiwan, Ltd. (ScinoPharm).
•  Any opinions expressed in this material are
  subject to change without notice as a result of
  using different assumptions. ScinoPharm is under
  no obligation to update or keep current the
  information contained herein. The information
  contained in this presentation is ScinoPharms
  confidential information.
• Any disclosure, copying, distribution or any
  action taken or omitted to be taken in reliance
  on it is prohibited and may be unlawful.
•  No representation or warranty, express or
  implied, is or will be made in or in relation to,
  and no responsibility or liability is or will be
  accepted by the Company as to, the accuracy or
  completeness of this material and any liability
  therefore is hereby expressly disclaimed.
•  Statements made in this material include
  forward-looking statements, which include,
  without limitation, statements about the issues,
  plans and expectations of ScinoPharm. Without
  limiting the foregoing, statements including the
  words believes, anticipates, plans,
  expects and similar expressions are also
  forward-looking statements. Forward-looking
  statements reflect, among other things,
  managements plans and objectives for future
  operations, current views with respect to future
  events and future economic performances and
  projections of various financial items. These
  forward-looking statements involve known and
  unknown risks, uncertainties and other factors
  which may cause actual results to differ
  materially from those implied by such
  forward-looking statements.

3
ScinoPharm

• Sales doubling every year, fueled by both
  generic brand businesses
• gt 60 Customers worldwide
• gt 150 scientists 24 generic APIs, targeting
  10 new APIs per year
• Products include small molecules, peptides
  proteins
• Specializing in high potency injectable
• Total commitment to IP protection
• Combined advantages of China and Taiwan
• FDA approved

4
ScinoPharms Vision

• Leading provider of API services for major
  pharma companies
• Contract Process RD and Clinical Supplies
• Contract Manufacturing
• Dominant player in generic API market
• Supplying small molecules, peptides,
  biopharmaceutical services

5
API Market

• US24 billion contract manufacturing needs
• US15 billion - Off-patent APIs
• US6 billion Advanced intermediates
  custom made APIs
• US3 billion Basic building blocks
• Increased outsourcing of early stage
  clinicals helps accelerate NCE development
• Suppliers shifting to Asia at equal quality at
  lower cost

6
Business Strategies

• Maintain balance between generic brand
  business, non-competing on same product
• Provide comprehensive (life-cycle) services to
  brand pharma from clinical materials to
  commercial
• Focus on generic APIs with high technological
  barriers
• Increase valuation with royalties from joint
  development of generic APIs with strategic
  partners
• Provide low cost RD and manufacturing of early
  steps in China coupled with high quality,
  IP- protected GMP production in Taiwan

7
Why Taiwan ?

• Intellectual property protection , ranked 4
  country of patent granted in US
• National strategic commitment availability of
  government funds
• Numerous incentives (tax, RD grant, loans,
  land)
• Success in high tech industry (computers,
  electronics)
• Abundance of US-trained professionals
• Education quality in science among best in the
  world
• Business flexibility English language skills
• Lower cost design/construct - 25-30 of US

8
Why China ?

• Abundance of low cost, high quality RD
  resources
• Low cost supplies of raw materials
  building blocks
• Low cost supplies of process technologies
  custom synthesis for key intermediates
• Source of new drug leads from natural
  products
• Chinese facility with locally made equipment
  offer major savings

9
Company Formation

• Founded managed by ex-Syntex executives
• Jo Shen President CEO, 30 yrs in
  Chemical/Pharma industry, ex-Syntex
• Corporate VP of Operations
• Hardy Chan Chief Scientific Officer, 30 yrs in
  Pharma industry, ex-Syntex
• VP of
  Research/Biotechnology
• Bob Ells Advisor, 35 yrs in Chemical/Pharma
  industry, ex-Syntex President
• of Manufacturing
• Bob Cook Advisor, 40 yrs in Pharma industry,
  ex-Syntex Director of
  Marketing
• Major shareholders include the Uni-President
  group (the largest food conglomerate in
  Taiwan), Taiwanese government, employees
  US investors
• Started in 11/97, built a state-of-the-art API
  RD and cGMP manufacturing facility in
  Taiwan plus an RD center in China

10
ScinoPharm in Taiwan
11
ScinoPharm in China
12
Production Facilities
13
Company Status

• 500 people in Taiwan China (near Shanghai)
  with 150 in RD
• Taiwan facility received US FDA approval
• Developed 24 generic APIs with 10 new APIs
  per year, expects 3-5 launches per year
• 16 US DMFs, 5 to file in 2005, 11 process
  patents filed and 6 granted
• Produce 40 NCEs clinical supplies to date,
  with 5 in phase III
• Entered into gt20 long term supply agreements
  with brand and generic customers

14
ScinoPharms APIs

• Oncological
• Gastrointestinal
• Hormonal
• Urinary
• Anti-inflammatory
• Sleep Disorders
• CNS

Detailed Product List Available in Website
15
Competitive Advantages

• Development of novel technologies for unmet
  industry needs
• Specializing in high potency injectables
• Combination of cost advantages from China
  GMP/IP/EHS compliance in Taiwan
• Rich generic pipeline driven by large low cost
  RD
• Investment incentives in Taiwan
• Familiarity with drug development regulatory
  requirements
• Existence of broad client base

16
Long Term Goals

• Become a technology-based strategic partner
  to generic and brand companies
• Expand Asian-based manufacturing
• Acquire companies to expand technology or
  product portfolio
• Provide NCE companies with unique chemical
  scaffolds based on Chinese medicines
• Extend into special formulations as a service
  provider
• Enter into Chinese market with unique dosage
  forms

17
Summary

• Major hurdles surpassed
• capital
• product development
• customer base
• Strong Western management team
• State-of-the-art API facilities in low-cost
  Asia
• Highly cost-effective RD
• Tapped into bourgeoning science and
  resources of Greater China

18
Thank You!!